Recludix Pharma, Inc., a platform provider for the discovery of inhibitors of challenging targets for inflammatory disease and cancer, has entered a strategic collaboration with Sanofi US to develop and commercialize oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for immunological and inflammatory (I&I) diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.   Sanofi will have global rights to small mole...